The AIDS epidemic has been a global public health issue for more than 40 years and has
resulted in~ 40 million deaths. AIDS is caused by the retrovirus, HIV-1, which is transmitted …

After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Background Oral pre-exposure prophylaxis has been introduced in more than 70 countries,
including many in sub-Saharan Africa, but women experience considerable barriers to daily …

Vaccines represent the single most cost-efficient and equitable way to combat and eradicate
infectious diseases. While traditional licensed vaccines consist of either …

Human diseases, particularly infectious diseases and cancers, pose unprecedented
challenges to public health security and the global economy. The development and …

The development of antiretroviral therapy for the prevention and treatment of HIV infection
has been marked by a series of remarkable successes. However, the efforts to develop a …

The current prevention efforts for STIs, HIV and viral hepatitis in the WHO European Region,
especially in the Central and Eastern subregions, are hindered by healthcare disparities …

The initial development of cytomegalovirus (CMV) as a vaccine vector for HIV/simian
immunodeficiency virus (SIV) was predicated on its potential to pre-position high-frequency …

Different mechanisms mediate the toxicity of RNA. Genomic retroviral mRNA hijacks infected
host cell factors to enable virus replication. The viral genomic RNA of the human …

The VRC01 Antibody Mediated Prevention (AMP) efficacy trials conducted between 2016
and 2020 showed for the first time that passively administered broadly neutralizing …